Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis

Ítems similars

• Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis
  per: Wouters C, et al.
  Publicat: (2011-09-01)
• The Efficacy of Combination Therapy by Adalimumab with Methotrexate and of Monotherapy by Methotrexate for Children Suffering from Polyarticular Juvenile Idiopathic Arthritis
  per: V. A. Keltsev, et al.
  Publicat: (2016-01-01)
• Comparative efficacy and safety of etanercept and adalimumab in the treatment of polyarticular juvenile idiopathic arthritis
  per: Lanlan Ge, et al.
  Publicat: (2025-03-01)
• Correction: Comparative efficacy and safety of etanercept and adalimumab in the treatment of polyarticular juvenile idiopathic arthritis
  per: Lanlan Ge, et al.
  Publicat: (2026-05-01)
• COMPARATIVE EVALUATION OF THE EFFICACY AND SAFETY OF TREATMENT USING ADALIMUMAB IN COMBINATION WITH METHOTREXATE AND METHOTREXATE MONOTHERAPY IN CHILDREN WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN COMBINATION WITH UVEITIS
  per: V. А. Kel’tsev, et al.
  Publicat: (2014-12-01)